<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39375384</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines.</ArticleTitle><Pagination><StartPage>183</StartPage><MedlinePgn>183</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">183</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00980-3</ELocationID><Abstract><AbstractText>Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow adequate time for production in eggs. RNA vaccines offer the potential to accelerate production and improve efficacy of influenza vaccines. We leveraged the nucleoside-modified RNA (modRNA) platform technology and lipid nanoparticle formulation process of the COVID-19 mRNA vaccine (BNT162b2; Comirnaty®) to create modRNA vaccines encoding hemagglutinin (HA) (modRNA-HA) for seasonal human influenza strains and evaluated their preclinical immunogenicity and toxicity. In mice, a monovalent modRNA vaccine encoding an H1 HA demonstrated robust antibody responses, HA-specific Th1-type CD4<sup>+</sup> T cell responses, and HA-specific CD8<sup>+</sup> T cell responses. In rhesus and cynomolgus macaques, the vaccine exhibited durable functional antibody responses and HA-specific IFN-γ<sup>+</sup> CD4<sup>+</sup> T cell responses. Immunization of mice with monovalent, trivalent, and quadrivalent modRNA-HA vaccines generated functional antibody responses targeting the seasonal influenza virus(es) encoded in the vaccines that were greater than, or similar to, those of a licensed quadrivalent influenza vaccine. Monovalent and quadrivalent modRNA-HA vaccines were well-tolerated by Wistar Han rats, with no evidence of systemic toxicity. These nonclinical immunogenicity and safety data support further evaluation of the modRNA-HA vaccines in clinical studies.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hauguel</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sharma</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrocola</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowry</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maddur</LastName><ForeName>Mohan S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Cheng Hui</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Swati</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8794-4300</Identifier><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitsky</LastName><ForeName>Allison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6888-789X</Identifier><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Shambhunath</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manickam</LastName><ForeName>Balasubramanian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Groton, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Souza</LastName><ForeName>Ivna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chervona</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Raquel Munoz</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdon</LastName><ForeName>Charisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcao</LastName><ForeName>Larissa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tompkins</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illenberger</LastName><ForeName>Deanne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fanyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efferen</LastName><ForeName>Kari Sweeney</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markiewicz</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Groton, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umemoto</LastName><ForeName>Cinthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jianfang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Biometrics &amp; Data Management, Pfizer Inc., Collegeville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scully</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0009-0007-2627-6581</Identifier><AffiliationInfo><Affiliation>Drug Safety Research &amp; Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Annaliesa S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-6413-1718</Identifier><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suphaphiphat Allen</LastName><ForeName>Pirada</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA. Pirada.Allen@pfizer.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>All authors are current or former employees of Pfizer Inc., and may, as a consequence, be shareholders. Pfizer was involved in the design, analysis, and interpretation of the data in this research study, the writing of this report, and the decision to publish. PSA is an inventor on a patent application related to nucleoside-modified RNA LNP vaccines encoding influenza hemagglutinin.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375384</ArticleId><ArticleId IdType="pmc">PMC11488230</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00980-3</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00980-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paget, J. et al. Global and national influenza-associated hospitalisation rates: estimates for 40 countries and administrative regions. J. Glob. Health13, 04003 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9879557</ArticleId><ArticleId IdType="pubmed">36701368</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet391, 1285–1300 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935243</ArticleId><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Disease Burden of Flu, https://www.cdc.gov/flu/about/burden/ (2023).</Citation></Reference><Reference><Citation>Kostova, D. et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS ONE8, e66312 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686813</ArticleId><ArticleId IdType="pubmed">23840439</ArticleId></ArticleIdList></Reference><Reference><Citation>Carias, C. et al. Net Costs Due to Seasonal Influenza Vaccination-United States, 2005-2009. PLoS ONE10, e0132922 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521706</ArticleId><ArticleId IdType="pubmed">26230271</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season, https://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza (2024).</Citation></Reference><Reference><Citation>WHO. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season, https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season (2024).</Citation></Reference><Reference><Citation>Dou, D., Revol, R., Ostbye, H., Wang, H. &amp; Daniels, R. Influenza A virus cell entry, replication, virion assembly and movement. Front. Immunol.9, 1581 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6062596</ArticleId><ArticleId IdType="pubmed">30079062</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, C. A. et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine26, D31–D34 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19230156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA114, 12578–12583 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703309</ArticleId><ArticleId IdType="pubmed">29109276</ArticleId></ArticleIdList></Reference><Reference><Citation>USDA. Avian influenza outbreaks reduced egg production, driving prices to record highs in 2022, https://www.ers.usda.gov/data-products/chart-gallery/gallery/chart-detail/?chartId=105576 (2022).</Citation></Reference><Reference><Citation>Chen, J. R., Liu, Y. M., Tseng, Y. C. &amp; Ma, C. Better influenza vaccines: an industry perspective. J. Biomed. Sci.27, 33 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7023813</ArticleId><ArticleId IdType="pubmed">32059697</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. CDC Vaccine Price List, https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html (2024).</Citation></Reference><Reference><Citation>Scorza, F. B. &amp; Pardi, N. New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines (Basel)610.3390/vaccines6020020 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027361</ArticleId><ArticleId IdType="pubmed">29614788</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. COVID-19 Vaccine Development: Behind the Scenes, https://covid19.nih.gov/news-and-stories/vaccine-development (2020).</Citation></Reference><Reference><Citation>Walsh, E. E. et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl. J. Med.383, 2439–2450 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature592, 283–289 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J. Med.383, 2603–2615 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature595, 572–577 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, D. et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine21, 2830–2836 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12798624</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll, T. D. et al. Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant. J. Infect. Dis.209, 24–33 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864389</ArticleId><ArticleId IdType="pubmed">24141979</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll, T. D. et al. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone (R) in rhesus macaques. Vaccine29, 931–940 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026063</ArticleId><ArticleId IdType="pubmed">21111777</ArticleId></ArticleIdList></Reference><Reference><Citation>Coe, C. L., Lubach, G. R. &amp; Kinnard, J. Immune senescence in old and very old rhesus monkeys: reduced antibody response to influenza vaccination. Age34, 1169–1177 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448997</ArticleId><ArticleId IdType="pubmed">22231440</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. A., McClements, W., Ulmer, J. B., Shiver, J. &amp; Donnelly, J. Immunization of non-human primates with DNA vaccines. Vaccine15, 909–912 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9234545</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, A. S., Taubenberger, J. K. &amp; Bray, M. The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. Antiviral Res.117, 75–98 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4462516</ArticleId><ArticleId IdType="pubmed">25746173</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season, https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2021-2022-northern-hemisphere-influenza-season (2021).</Citation></Reference><Reference><Citation>WHO. Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season, https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season (2022).</Citation></Reference><Reference><Citation>Rohde, C. M. et al. Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. Vaccines1110.3390/vaccines11020417 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9965811</ArticleId><ArticleId IdType="pubmed">36851293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, A. et al. Isocitrate treatment of acute anemia of inflammation in a mouse model. Blood Cells Mol. Dis56, 31–36 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660302</ArticleId><ArticleId IdType="pubmed">26603720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, A. et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood123, 1129–1136 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9632791</ArticleId><ArticleId IdType="pubmed">24357728</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, M. B. et al. Non-lethal endotoxin injection: a rat model of hypercoagulability. PLoS ONE12, e0169976 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233421</ArticleId><ArticleId IdType="pubmed">28081568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett, K. J. et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids15, 1–11 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383180</ArticleId><ArticleId IdType="pubmed">30785039</ArticleId></ArticleIdList></Reference><Reference><Citation>Everds, N. E. et al. Interpreting stress responses during routine toxicity studies: a review of the biology, impact, and assessment. Toxicol Pathol.41, 560–614 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23475558</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA. Comirnaty EPAR Public Assessment Report, https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf (2021).</Citation></Reference><Reference><Citation>Skowronski, D. M. et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE9, e92153 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965421</ArticleId><ArticleId IdType="pubmed">24667168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther.25, 1316–1327 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5475249</ArticleId><ArticleId IdType="pubmed">28457665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun.9, 3361 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105651</ArticleId><ArticleId IdType="pubmed">30135514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kackos, C. M. et al. Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection. NPJ Vaccines8, 157 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10570305</ArticleId><ArticleId IdType="pubmed">37828126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines6, 153 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677760</ArticleId><ArticleId IdType="pubmed">34916519</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn, J. A. et al. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates. Vaccine40, 4412–4423 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35680500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang, X. et al. mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice. Vaccines8, 10.3390/vaccines8010123 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157730</ArticleId><ArticleId IdType="pubmed">32164372</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong, F. et al. An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses. Emerg. Microbes Infect.12, 2256422 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10512870</ArticleId><ArticleId IdType="pubmed">37671994</ArticleId></ArticleIdList></Reference><Reference><Citation>Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol.30, 1210–1216 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23159882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson, D., Curry, R. L., Beare, A. S. &amp; Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg.70, 767–777 (1972).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2130285</ArticleId><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khayatt, R., Jennings, R. &amp; Potter, C. W. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J. Hyg.93, 301–312 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2129441</ArticleId><ArticleId IdType="pubmed">6389697</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl. J. Med.383, 1544–1555 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell185, 2434–2451.e2417 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science374, eabj9853 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542617</ArticleId><ArticleId IdType="pubmed">34519540</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevo, C. Second Quarter 2022 Earnings Teleconference, https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf (2022).</Citation></Reference><Reference><Citation>Jansen, J. M., Gerlach, T., Elbahesh, H., Rimmelzwaan, G. F. &amp; Saletti, G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol.119, 44–52 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31491709</ArticleId></ArticleIdList></Reference><Reference><Citation>He, X. S. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol.80, 11756–11766 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1642596</ArticleId><ArticleId IdType="pubmed">16971435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoft, D. F. et al. Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults. Clin. Vaccine Immunol.24, 10.1128/CVI.00414-16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216430</ArticleId><ArticleId IdType="pubmed">27847366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobby, J. L., Danzy, S., Holmes, K. E., Lowen, A. C. &amp; Kohlmeier, J. E. Both humoral and cellular immunity limit the ability of live attenuated influenza vaccines to promote T Cell responses. J. Immunol.212, 107–116 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10842048</ArticleId><ArticleId IdType="pubmed">37982700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. &amp; Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl Acad. Sci. USA97, 6108–6113 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18566</ArticleId><ArticleId IdType="pubmed">10801978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>